Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.
about
Current perspectives on HIV-1 antiretroviral drug resistanceDifferential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and CHigh-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South AfricaHigh prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South AfricaStandardized representation, visualization and searchable repository of antiretroviral treatment-change episodesHIV-1 drug resistance and resistance testing.Determination of Phenotypic Resistance Cutoffs From Routine Clinical DataOccult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutationsDevelopment of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.HIV-1 antiretroviral resistance: scientific principles and clinical applicationsDrug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.Acyclic nucleoside phosphonates: a key class of antiviral drugs.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Tenofovir disoproxil fumarate for the treatment of HIV infection.Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study.Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovirCharacterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China.Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudineHIV-1 drug resistance mutations: an updated framework for the second decade of HAARTPanel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations.Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settingsEvolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to preventionPrevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis.Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.HIV drug resistance levels in adults failing first-line antiretroviral therapy in an urban and a rural setting in South Africa.2014 Update of the drug resistance mutations in HIV-1Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
P2860
Q26852626-EFF67497-6D85-4EFB-AA5F-AC615A9CD381Q28484213-E9472C82-1311-4B43-8EAD-E6CBBEF3682AQ28535483-815CB1CA-A6E0-4BE7-89AE-0BFA17EC3C88Q28543358-F9A03E53-A8CF-4844-A426-92E8E97B2620Q28727940-AB9D5DB5-B14C-4CB7-9DC3-AACD61C0540FQ30245693-069E6C1A-8BAE-4B7C-95B8-A84BA16BC451Q31139379-A4BC02E1-6A5C-4D26-973F-0C2F8743A8F5Q33647567-ACB614CE-776B-4CEA-89A2-479FE51A7264Q33867773-078E9502-9F2A-4F3F-A926-730E0E009703Q33962846-2EE395C3-B166-4CF3-B947-9575D6320E95Q34280466-41DD8430-D901-4109-A215-8C0929EBFD4CQ34303603-1785D473-0C3F-4DB0-9367-2AAE65271332Q34464655-CBC18B48-7961-4FF8-8024-D28FC4172EEBQ34489239-53B8A8CE-4360-4CCD-9883-4B2B79F36F4EQ34569309-A750BD35-7746-4A23-8E36-F5B197634BA5Q34717892-BBDE5621-253E-4EBA-8119-9116ADC7D235Q35057734-505F9404-C72F-4E70-B99F-6785123A8DF5Q35752812-6DCA7882-DFCB-4BDF-9CA9-44DB1E3290DAQ35912746-32D181F8-6B2E-40F8-BA73-87F762615518Q36076011-79E53F2C-5305-43F1-9B21-5D2EB2019450Q36134243-3452BCD0-B79C-47EA-A2F8-5B0824C9DAA6Q36250342-BD8F4F76-D5CF-445D-AB89-3EF8DFC4E051Q36347325-DE00183D-CD6A-40EC-ACAD-C8FBBFC78564Q36632238-32D89D42-6896-44E9-9D3F-D4A72DF4A49BQ36852626-E24183D4-E5E5-481C-9224-BF2A6C0E85A5Q36900010-3CBADF48-A493-497C-948D-C612DA56255BQ36950131-8C146B00-BBC6-46D9-9314-37EC2532E216Q37003942-A013F300-C1DA-4F1C-A768-EC17DD8984E8Q37071435-602B13D6-81E6-430E-B549-E36B7EE58347Q37216229-AA202305-DDCF-486A-AD3B-2F4BC581E025Q37216235-2DBF1186-1EFF-4D9E-9943-38710A9FD7C9Q37256719-7A542FD7-F75A-438F-8659-EE2D441AB48CQ37332192-80DACA66-DCE7-4204-AD9A-2D13FA1942B0Q37859395-F2649705-53BE-48F8-B6AB-9245C9E3FD8FQ38848190-AE04D658-26BF-406B-8900-52F1152B4CB0Q38854117-230730D8-6FAB-4E60-A9FF-7C467B97A4C9Q39410515-A16C6636-70A9-49EF-9CCF-9354E73B2D7CQ39498339-9BACB78F-FE1A-4083-B773-62E168B206DCQ40104085-9E5B3575-7C61-4341-83C7-D45A851F10DBQ40223002-0B356C7D-AF7F-435D-8FCC-EAB1BA88B6FE
P2860
Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Genotypic and phenotypic predi ...... troviral-experienced patients.
@en
Genotypic and phenotypic predi ...... troviral-experienced patients.
@nl
type
label
Genotypic and phenotypic predi ...... troviral-experienced patients.
@en
Genotypic and phenotypic predi ...... troviral-experienced patients.
@nl
prefLabel
Genotypic and phenotypic predi ...... troviral-experienced patients.
@en
Genotypic and phenotypic predi ...... troviral-experienced patients.
@nl
P2093
P356
P1476
Genotypic and phenotypic predi ...... troviral-experienced patients.
@en
P2093
Andrew Cheng
Lijie Zhong
Michael D Miller
Michael Wulfsohn
Nicolas Margot
Shan-Shan Chen
P304
P356
10.1086/381784
P407
P577
2004-02-10T00:00:00Z